Compound sustained-release preparation containing succinate Frovatriptan

A frovatriptan succinate, slow-release preparation technology, applied in the field of pharmaceutical preparations, can solve the problem that pain stimulation cannot reach nerve endings

Inactive Publication Date: 2015-04-22
CP PHARMA QINGDAO CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

(2) Blocking or stuffing the painful nerve endings so that painful stimuli cannot reach the nerve endings

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Prescription 1 (according to 1000 capsules)

[0012] A. Frotriptan succinate immediate release granules

[0013] Frotriptan Succinate 1.0g

[0014] Microcrystalline Cellulose 10.0g

[0015] Lactose 12.95g

[0016] Crospovidone 0.9g

[0017] Magnesium stearate 0.15g

[0018] B. Frotriptan succinate sustained-release granules

[0019] Frotriptan succinate 2.91g

[0020] Hydroxypropyl methylcellulose 12.5g

[0021] Carbomer 2.0g

[0022] Lactose 8.5g

[0023] Magnesium stearate 0.25g

[0024] C. Aspirin sustained-release granules

[0025] Aspirin 100g

[0026] Hydroxypropyl Methyl Cellulose 25g

[0027] Carbomer 2.5g

[0028] Lactose 22.5g

[0029] Magnesium stearate 0.25g

[0030] Preparation method: crush frovatriptan succinate and aspirin through an 80-mesh sieve, then mix the sustained-release materials evenly, crush them through a 120-mesh sieve, and then mix frovatriptan succinate with the sustained-release materials to prepare immediate-release granul...

Embodiment 2

[0032] Prescription 2 (according to 1000 capsules)

[0033] A. Frotriptan succinate immediate release granules

[0034] Frotriptan Succinate 1.0g

[0035] Microcrystalline Cellulose 10.0g

[0036] Lactose 12.95g

[0037] Crospovidone 0.9g

[0038] Magnesium stearate 0.15g

[0039] B. Frotriptan succinate sustained-release granules

[0040] Frotriptan succinate 2.91g

[0041] Hydroxypropyl methylcellulose 10.5g

[0042] Carbomer 6.0g

[0043] Lactose 12.5g

[0044] Magnesium stearate 0.3g

[0045] C. Aspirin sustained-release granules

[0046] Aspirin 100g

[0047] Hydroxypropyl Methyl Cellulose 30g

[0048] Carbomer 8.5g

[0049] Lactose 12.5g

[0050] Magnesium stearate 0.25g

[0051] Preparation method is the same as embodiment 1.

Embodiment 3

[0053] Prescription 3 (according to 1000 capsules)

[0054] A. Frotriptan succinate immediate release granules

[0055] Frotriptan Succinate 1.0g

[0056] Microcrystalline Cellulose 10.0g

[0057] Lactose 12.95g

[0058] Crospovidone 0.9g

[0059] Magnesium stearate 0.15g

[0060] B. Frotriptan succinate sustained-release granules

[0061]Frotriptan succinate 2.91g

[0062] Hydroxypropyl methylcellulose 7.5g

[0063] Carbomer 1.5g

[0064] Lactose 18.5g

[0065] Magnesium stearate 0.3g

[0066] C. Aspirin sustained-release granules

[0067] Aspirin 100g

[0068] Hydroxypropyl Methyl Cellulose 35g

[0069] Carbomer 10.5g

[0070] Lactose 8.5g

[0071] Magnesium stearate 0.3g

[0072] Preparation method is the same as embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicine preparations, and in particular relates to a sustained-release preparation of a compound medicine containing succinate Frovatriptan and aspirin. The sustained-release preparation is characterized by consisting of two parts namely a quick release part and a sustained release part, wherein after the sustained-release preparation enters a human body, the quick release part is rapidly released to achieve a certain blood medicine concentration, and the sustained release part is slowly released to maintain a certain blood medicine concentration, so that good medicine effects can be achieved, and side effects of the medicine can also be effectively avoided. The sustained-release preparation disclosed by the invention has the advantages of quick dissolution, fast absorption, high biological availability, good stability, convenience in taking and the like. The invention also discloses a preparation method of the compound medicine.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a compound slow-release preparation containing frovatriptan succinate, which belongs to the technical field of medicine. Background technique [0002] Migraine is the most common type of primary headache clinically. The main clinical manifestation is paroxysmal moderate to severe, throbbing headache. The headache is mostly hemilateral and usually lasts for 4-72 hours. Headaches can be aggravated by stimuli or everyday activities and relieved by quiet surroundings and rest. Migraine is a common chronic neurovascular disease. Its onset is mostly in children and adolescence, and it reaches the peak in young and middle-aged adults. It is more common in women. The prevalence rate in the population is 5%-10%, and it often has a genetic background. [0003] Migraine is primarily caused by central nervous system dysfunction, and vascular changes are secondary. Migraine attacks...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/616A61K9/52A61P25/06A61P29/00A61K31/403
CPCA61K31/616A61K31/403
Inventor 王明刚任莉陈阳生刘晓霞孙桂玉臧云龙
Owner CP PHARMA QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap